Published 1985
| Version v1
Report
Restricted
Radiopharmaceutical drug review process
Description
To ensure proper radioactive drug use (such as quality, diagnostic improvement, and minimal radioactive exposure), the Food and Drug Administration evaluates new drugs with respect to safety, effectiveness, and accuracy and adequacy of the labeling. The IND or NDA process is used for this purpose. A brief description of the process, including the Chemical Classification System and the therapeutic potential classification, is presented as it applies to radiopharmaceuticals. Also, the status of the IND or NDA review of radiopharmaceuticals is given
Files
Additional details
Publishing Information
- Imprint Title
- Developing role of short-lived radionuclides in nuclear medical practice. DOE symposium series: 56
- Journal Page Range
- p. 54-57.
- Report number
- CONF-820523--
Conference
- Title
- International symposium on the developing role of short-lived radionuclides in nuclear medical practice.
- Dates
- 3-5 May 1982.
- Place
- Washington, DC (USA).
INIS
- Country of Publication
- United States
- Country of Input or Organization
- United States
- INIS RN
- 17019264
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Resource subtype / Literary indicator
- Conference
- Descriptors DEI
- ORGANIZING; QUALITY CONTROL; RADIOPHARMACEUTICALS; RECOMMENDATIONS; US FDA
- Descriptors DEC
- CONTROL; DRUGS; LABELLED COMPOUNDS; MATERIALS; NATIONAL ORGANIZATIONS; RADIOACTIVE MATERIALS; US ORGANIZATIONS